Pretreatment Circulating Vascular Biomarkers Predict Cancer Therapy–Related Cardiac Dysfunction During HER2+ Breast Cancer Treatment
Authors' conclusion
Pretreatment endothelial-centric and inflammatory biomarkers outperformed both clinical and CMR measures in predicting CTRCD during chemotherapy.
Study context
- Population
- Women with early-stage HER2+ breast cancer receiving anthracycline and trastuzumab therapyvalidation cohort n = 38
- Participants
- 136 women
- Exposure
- Patients who developed cancer therapy-related cardiac dysfunction (CTRCD) vs those who did not
- Outcome
- CMR-defined CTRCD (by LVEF on CMR)
- Follow-up
- Within 15 months
Methodological detailsdiscovery and validation cohorts, multiomics profiling, random forest model
- Discovery and validation cohorts
- Multiomics profiling
- Random forest model
Main finding
As reported in the abstract
CMR-defined CTRCD
Developed CMR-defined CTRCD
37
27.2%
Observational data: associations, not effects.
Further findings
Pretreatment plasma microRNAs
- Distinct CTRCD-associated signatures
Original publication
Pretreatment Circulating Vascular Biomarkers Predict Cancer Therapy–Related Cardiac Dysfunction During HER2+ Breast Cancer Treatment. JACC CardioOncol. Published 15 December 2025. doi:10.
Summarised from the published abstract; every number is checked against it